Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

González-Martín, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; Mccormick, Colleen C.; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andrés; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Malinowska, Izabela A.; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R.; Monk, Bradley J.